Erlotinib Completed Phase 2 Trials for Type 2 Papillary Renal Cell Carcinoma / Stage IV Renal Cell Cancer / Childhood Renal Cell Carcinoma / Renal Cell Carcinoma Recurrent / Stage III Renal Cell Cancer / Type 1 Papillary Renal Cell Carcinoma Treatment

CompletedTreatment2 IdentifierTitleDrugs
NCT01688973Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery